X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (69) 69
oncology (37) 37
hematology (27) 27
male (26) 26
female (24) 24
middle aged (21) 21
adult (18) 18
aged (16) 16
apoptosis (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
apoptosis - drug effects (13) 13
index medicus (12) 12
chemotherapy (11) 11
apoptosis regulatory proteins (10) 10
antineoplastic agents - pharmacology (9) 9
expression (9) 9
cancer (8) 8
immunology (8) 8
immunotherapy (8) 8
intracellular signaling peptides and proteins (8) 8
treatment outcome (8) 8
tumor cells, cultured (8) 8
activation (7) 7
chronic lymphocytic-leukemia (7) 7
flow cytometry (7) 7
par-4 (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
bcl-2 (6) 6
bendamustine (6) 6
care and treatment (6) 6
carrier proteins - genetics (6) 6
carrier proteins - physiology (6) 6
caspases - metabolism (6) 6
daxx (6) 6
disease-free survival (6) 6
dose-response relationship, drug (6) 6
doxorubicin - pharmacology (6) 6
drug synergism (6) 6
fludarabine (6) 6
interleukin-2 (6) 6
jurkat cells (6) 6
molecular sequence data (6) 6
remission induction (6) 6
rituximab (6) 6
survival (6) 6
t-lymphocytes, cytotoxic - immunology (6) 6
acute disease (5) 5
adaptor proteins, signal transducing (5) 5
base sequence (5) 5
carrier proteins - biosynthesis (5) 5
cytotoxicity, immunologic (5) 5
death (5) 5
disease (5) 5
drug administration schedule (5) 5
gene expression (5) 5
in-vitro (5) 5
inhibitor of apoptosis proteins (5) 5
interleukin-2 - therapeutic use (5) 5
lymphomas (5) 5
melanoma - immunology (5) 5
neoplasm staging (5) 5
non-hodgkins-lymphoma (5) 5
polymerase chain reaction (5) 5
proteins - metabolism (5) 5
proto-oncogene proteins c-bcl-2 - metabolism (5) 5
receptors, antigen, t-cell, alpha-beta - genetics (5) 5
recurrence (5) 5
therapy (5) 5
transfection (5) 5
antigens (4) 4
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - pharmacology (4) 4
bendamustine hydrochloride (4) 4
carrier proteins - metabolism (4) 4
caspases (4) 4
cd8-positive t-lymphocytes - immunology (4) 4
cladribine (4) 4
cyclophosphamide (4) 4
cyclophosphamide - administration & dosage (4) 4
cytotoxicity (4) 4
dendritic cells (4) 4
disease progression (4) 4
doxorubicin - administration & dosage (4) 4
gene expression regulation, neoplastic (4) 4
interleukin-2 - pharmacology (4) 4
kidney neoplasms - therapy (4) 4
leukemia (4) 4
lymphocytes, tumor-infiltrating - immunology (4) 4
lymphoma (4) 4
lymphoma, non-hodgkin - drug therapy (4) 4
melanoma - therapy (4) 4
mice (4) 4
neoplasm proteins - genetics (4) 4
neoplasms - immunology (4) 4
neoplasms - therapy (4) 4
peripheral-blood (4) 4
pharmacology & pharmacy (4) 4
recombinant interleukin-2 (4) 4
rna, messenger - analysis (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Journal Article
by Horwitz, Steven and O'Connor, Owen A and Pro, Barbara and Illidge, Tim and Fanale, Michelle and Advani, Ranjana and Bartlett, Nancy L and Christensen, Jacob Haaber and Morschhauser, Franck and Domingo-Domenech, Eva and Rossi, Giuseppe and Kim, Won Seog and Feldman, Tatyana and Lennard, Anne and Belada, David and Illés, Árpád and Tobinai, Kensei and Tsukasaki, Kunihiro and Yeh, Su-Peng and Shustov, Andrei and Hüttmann, Andreas and Savage, Kerry J and Yuen, Sam and Iyer, Swaminathan and Zinzani, Pier Luigi and Hua, Zhaowei and Little, Meredith and Rao, Shangbang and Woolery, Joseph and Manley, Thomas and Trümper, Lorenz and Aboulafia, David and Advani, Ranjana and Alpdogan, Onder and Ando, Kiyoshi and Arcaini, Luca and Baldini, Luca and Bellam, Naresh and Bartlett, Nancy and Belada, David and Yehuda, Dina Ben and Benedetti, Fabio and Borchman, Peter and Bordessoule, Dominique and Brice, Pauline and Briones, Javier and Caballero, Dolores and Carella, Angelo Michele and Chang, Hung and Cheong, June Weon and Cho, Seok-Goo and Choi, Ilseung and Choquet, Sylvain and Colita, Andrei and Congui, Angela Giovanna and D'amore, Francesco and Dang, Nam and Davison, Kelly and de Guibert, Sophie and Brown, Peter de Nully and Delwail, Vincent and Demeter, Judit and di Raimondo, Francesco and Do, Young Rok and Domingo, Eva and Douvas, Michael and Dreyling, Martin and Ernst, Thomas and Fanale, Michelle and Fay, Keith and Feldman, Tatyana and Ferrero, Silvia Fernandez and Flinn, Ian Winchester and Forero-Torres, Andres and Fox, Christopher and Friedberg, Jonathan and Fukuhara, Noriko and Garcia-Marco, Jose and Cruz, Jorge Gayoso and Codina, Jose Gomez and Gressin, Remy and Grigg, Andrew and Gurion, Ronit and Christensen, Jacob Haaber and Haioun, Corinne and Hajek, Roman and Hanel, Mathias and Hatake, Kiyohiko and Hensen, Robert and Horowitz, Netanel and Horwitz, Steven and Huttmann, Andreas and Illes, Arpad and Illidge, Tim and Ishizawa, Kenichi and Islas-Ohlmayer, Miguel and Jacobsen, Eric and Janakiram, Murali and Jurczak, Wojciech and Kaminski, Mark and ... and ECHELON-2 Study Group and ECHELON 2 Study Grp
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2010, Volume 126, Issue 4, pp. 909 - 918
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
Journal Article
International Journal of Hematology, ISSN 0925-5710, 11/2008, Volume 88, Issue 4, pp. 434 - 440
Epstein–Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune... 
Fludarabine | Medicine & Public Health | Hematology | Peripheral T-cell lymphoma | Oncology | Alemtuzumab | Secondary B-cell lymphoma | Epstein–Barr virus | AILT | Epstein-Barr virus | ALEMTUZUMAB CAMPATH-1H | ORGAN TRANSPLANT RECIPIENTS | RITUXIMAB | DISEASE | CHRONIC LYMPHOCYTIC-LEUKEMIA | ANGIOIMMUNOBLASTIC LYMPHADENOPATHY | LYMPHOPROLIFERATIVE DISORDERS | HEMATOLOGY | ANTI-CD52 MONOCLONAL-ANTIBODY | Lymphoma, T-Cell - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antibodies, Neoplasm - administration & dosage | Cytarabine - adverse effects | Virus Latency - drug effects | Cytarabine - administration & dosage | Herpesvirus 4, Human | Epstein-Barr Virus Infections - pathology | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - administration & dosage | Epstein-Barr Virus Infections - chemically induced | Lymphoma, T-Cell - pathology | Female | Neoplasms, Second Primary - drug therapy | Neoplasms, Second Primary - pathology | Antibodies, Neoplasm - adverse effects | Lymphoma, Large B-Cell, Diffuse - chemically induced | Viral antibodies | Antibodies | Care and treatment | Biological products | Non-Hodgkin's lymphomas | T cells | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 998 - 998
Abstract [§ share last authorship] Background: In 2000-2010, the first large prospective trials in peripheral T-cell lymphoma (PTCL) showed outcomes burdened... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 145 - 145
Abstract Introduction: Fludarabine plus rituximab (F-R) is an established treatment option for patients (pts) with relapsed/refractory follicular lymphoma... 
Journal Article